Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy (Q46834814)

25 December 2017

title

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy (English)

1 reference

25 December 2017

author name string

O Hans Iwenofu

1

1 reference

25 December 2017

Richard D Lackman

2

1 reference

25 December 2017

Arthur P Staddon

3

1 reference

25 December 2017

Diana G Goodwin

4

1 reference

25 December 2017

Helen M Haupt

5

1 reference

25 December 2017

John S J Brooks

6

1 reference

25 December 2017

publication date

21 December 2007

1 reference

25 December 2017

published in

Modern Pathology

1 reference

25 December 2017

volume

21

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

231-237

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/modpathol.3800995

exact match

0 references

cites work

Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

Primary bone osteosarcoma in the pediatric age: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Emerging drugs for the treatment of soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

mTOR, translational control and human disease.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Human cancer, PTEN and the PI-3 kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Targeting the molecular target of rapamycin (mTOR).

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Ribosomal S6 kinase signaling and the control of translation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

mTOR signaling: implications for cancer and anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Reproducibility of a histopathologic grading system for adult soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800995

7 January 2021

10.1038/MODPATHOL.3800995

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017